ライフサイエンスコーパス: lymphadenectomy

1 plus distal gastrectomy and retroperitoneal lymphadenectomy).

2 uding distal gastrectomy and retroperitoneal lymphadenectomy).

3 plus distal gastrectomy and retroperitoneal lymphadenectomy).

4 s compared with D2 resection (levels 1 and 2 lymphadenectomy).

5 ve esophagectomy resulted in a more extended lymphadenectomy.

6 ases who may benefit from immediate complete lymphadenectomy.

7 ection, whereas others only rarely recommend lymphadenectomy.

8 de count as a surrogate for a well performed lymphadenectomy.

9 d thus would benefit from esophagectomy with lymphadenectomy.

10 inel lymph node biopsy, and inguinal femoral lymphadenectomy.

11 d thyroid cancer, necessitating central neck lymphadenectomy.

12 of minimal access surgery for resection and lymphadenectomy.

13 , evidence supports the need for an adequate lymphadenectomy.

14 denectomy, and (2) from this, define optimum lymphadenectomy.

15 survival improved with increasing extent of lymphadenectomy.

16 egative FDG-PET/CT was confirmed by complete lymphadenectomy.

17 f stage III melanoma patients obtained after lymphadenectomy.

18 cancer and identifies patients for selective lymphadenectomy.

19 ositive nodes more frequently than a limited lymphadenectomy.

20 etastases, eliminating the need for invasive lymphadenectomy.

21 actors associated with obtaining an adequate lymphadenectomy.

22 those patients who did not have an adequate lymphadenectomy.

23 utic benefits of a complete versus selective lymphadenectomy.

24 ificantly less likely to receive an adequate lymphadenectomy.

25 on radical cystectomy with bilateral pelvic lymphadenectomy.

26 whose survival can be prolonged by immediate lymphadenectomy.

27 nsthoracic en bloc esophagectomy and 2-field lymphadenectomy.

28 ify and optimize the therapeutic benefits of lymphadenectomy.

29 o be related to surgical practice, primarily lymphadenectomy.

30 identifying patients who would benefit from lymphadenectomy.

31 hick primary cutaneous melanoma and sentinel lymphadenectomy.

32 onal study of esophagectomy with three-field lymphadenectomy.

33 lihood of lymph node metastases and requires lymphadenectomy.

34 lvic disease before planned surgical staging lymphadenectomy.

35 dentifies those who may benefit from earlier lymphadenectomy.

36 All patients underwent a complete axillary lymphadenectomy.

37 identification of all SLNs during selective lymphadenectomy.

38 lymphadenectomy with or without para-aortic lymphadenectomy.

39 most patients are unnecessarily subjected to lymphadenectomy.

40 d has been used as a surrogate for extent of lymphadenectomy.

41 tion (MILND) is a novel approach to inguinal lymphadenectomy.

42 py, transthoracic esophagectomy, and 2-field lymphadenectomy.

43 ations in patients who have a less extensive lymphadenectomy.

44 ts underwent PET/CT and pelvic and abdominal lymphadenectomy.

45 and group 3-a minimal abdominal and thoracic lymphadenectomy.

46 ewer patients to the morbidity of a complete lymphadenectomy.

47 be reviewed to determine the true extent of lymphadenectomy.

48 ndorse CA in selected patients undergoing D2 lymphadenectomy.

49 epresent a valuable tool for guiding salvage lymphadenectomy.

50 radical prostatectomy with bilateral pelvic lymphadenectomy.

51 vity (20.5% vs 25.9%, P = 0.01) and improved lymphadenectomy (16 vs 11 nodes, P < 0.01).

52 ic resections or gastrinoma enucleation with lymphadenectomy, 2 patients also had synchronous resecti

53 Within 3 months of sentinel lymphadenectomy, 270 (86.0%) of the 314 SLN-positive pat

54 Despite complete lymphadenectomy, 5-year overall survival (OS) for patien

55 ajor hepatectomy (82%), often accompanied by lymphadenectomy (67%) and sometimes by extrahepatic bile

56 A meticulous surgical lymphadenectomy adhering to well defined surgical bounda

57 retrieved and to determine if the extent of lymphadenectomy affects stage allocation and influences

58 The value of an extended lymphadenectomy after nCRT for esophageal cancer is deba

59 gional nodes, it is unclear whether extended lymphadenectomy after nCRT is still useful.

60 question the indication for maximization of lymphadenectomy after nCRT.

61 sthoracic esophagectomy with en bloc 2-field lymphadenectomy after neoadjuvant therapy were included,

62 atients underwent NIR-guided SLN mapping and lymphadenectomy after peritumoral ICG injection.

63 Immediate complete axillary lymphadenectomy (ALND) after sentinel lymphadenectomy (S

64 ned in patients undergoing complete axillary lymphadenectomy (ALND).

65 node negative NSCLC established via routine lymphadenectomy alone (n = 22).

66 ment have a low probability of survival with lymphadenectomy alone.

67 red with those who had hepatic resection and lymphadenectomy alone.

68 t draining cervical lymph nodes, as cervical lymphadenectomy also inhibited CD4(+) T cell-mediated dr

69 The absence of lymphadenectomy and assignment of histologic grade were

70 s who underwent hepatic resection along with lymphadenectomy and extra hepatic biliary resection had

71 plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymph

72 ients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on patholog

73 we discuss the complications associated with lymphadenectomy and identify subsets of low-risk patient

74 ancer patients undergoing esophagectomy with lymphadenectomy and investigating the effects of low and

75 rgone excision of the extrahepatic duct with lymphadenectomy and liver resection.

76 , necessity for vascular resection, regional lymphadenectomy and measures to minimize blood loss and

77 patients were surgically staged with pelvic lymphadenectomy and none received hormonal therapy befor

78 f 80 patients who underwent bilateral pelvic lymphadenectomy and radical cystectomy for bladder cance

79 es no difference in 5-year survival, however lymphadenectomy and reported surgical quality was subopt

80 , surgical resectional techniques, extent of lymphadenectomy and setting of specialized units and mul

81 he surgical techniques, improved adequacy of lymphadenectomy and some other minor factors such as mul

82 al Question: What is the association between lymphadenectomy and survival, disease recurrence, and su

83 iochemotherapy followed by complete regional lymphadenectomy and two postoperative courses of biochem

84 obot-assisted radical cystectomy with pelvic lymphadenectomy and urinary diversion for the treatment

85 o underwent radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metasta

86 relationship between survival and extent of lymphadenectomy, and (2) from this, define optimum lymph

87 ded endoscopic peritoneoscopy, liver biopsy, lymphadenectomy, and abdominal exploration.

88 thoracic nodes, group 2-a minimal abdominal lymphadenectomy, and group 3-a minimal abdominal and tho

89 ingle fraction of 20 Gy radiation, popliteal lymphadenectomy, and lymphatic vessel ablation.

90 However, issues like extent of resection, lymphadenectomy, and minimal access approach are still t

91 tive plan, including thyroidectomy, possible lymphadenectomy, and postoperative radioactive iodine ad

92 began vaccine therapy within 4 months after lymphadenectomy, and who had more complete data on the s

93 treated with radical hysterectomy and pelvic lymphadenectomy, and who had positive pelvic lymph nodes

94 benefits of radical cystectomy with extended lymphadenectomy, and will also examine the latest surgic

95 Compared to sham-operated animals, lymphadenectomy animals experienced significantly more h

96 Lymphadenectomy animals had significantly slower lymphat

97 Histological analysis of lymphadenectomy animals revealed 83% greater subcutis th

98 Pelvic lymphadenectomy appears to provide adequate nodal yield

99 benefits obtained by extending the limits of lymphadenectomy are compelling but inconclusive.

100 of adjuvant therapy should include extent of lymphadenectomy as a stratification factor.

101 Adequate lymphadenectomy, as measured by analysis of at least 15

102 101 (68)Ga-PSMA) originated from 73 salvage lymphadenectomies at biochemical recurrence and from 11

103 t biochemical recurrence and from 11 primary lymphadenectomies at radical prostatectomy.

104 934 melanoma patients who underwent sentinel lymphadenectomy at our institution from 1996 to 2003.

105 of life, and the optimal standard for pelvic lymphadenectomy at surgery.

106 etropubic prostatectomy and bilateral pelvic lymphadenectomy at the Mayo Clinic.

107 ale for surgeons to perform a more extensive lymphadenectomy at the time of initial thyroidectomy and

108 tomy as well as the optimal extent of pelvic lymphadenectomy at the time of radical cystectomy.

109 ph nodes and may benefit most from selective lymphadenectomy, avoiding the unnecessary complications

110 used 2 patient cohorts undergoing a template lymphadenectomy because of a PET/CT indicating LNM.

111 sality, and does not encourage more extended lymphadenectomy before further randomized evidence is ob

112 servative type of lymph node dissection), D2 lymphadenectomy (but not D3) is associated with better d

113 Laparoscopic prostatectomy with extended lymphadenectomy can be performed safely, retrieves a hig

114 Lymphatic mapping and sentinel lymphadenectomy can be successfully learned and applied

115 ion (WE) plus LM/SNB with immediate complete lymphadenectomy (CLND) for sentinel node (SN) metastases

116 e undergone radical prostatectomy and pelvic lymphadenectomy compared with those who received ADT onl

117 astases who have undergone prostatectomy and lymphadenectomy, compared with those who receive deferre

118 ET/CT to histopathology were identified from lymphadenectomies conducted in small anatomic subregions

119 of LN metastasis, the extent of surgery and lymphadenectomy could be limited and follow-up adjusted

120 vidence from randomised trials that extended lymphadenectomy (D2 gastric resection) confers a surviva

121 Comparative lymphadenectomy data for kidney and upper tract urotheli

122 elvic lymph node status, and extended pelvic lymphadenectomy dissection was necessary on the opposite

123 rextensive pelvic resection (extended pelvic lymphadenectomy dissection) in patients with localized P

124 Routine lymphadenectomy does not appear to yield benefit in kidn

125 rom randomized clinical trials suggests that lymphadenectomy does not improve survival or decrease di

126 Extended lymphadenectomy does not seem to confer a significant ov

127 ous worldwide data demonstrated that optimum lymphadenectomy during esophagectomy alone for esophagea

128 o assess the effect on survival of extent of lymphadenectomy during esophagectomy for patients underg

129 nd esophagogastric junction demonstrate that lymphadenectomy during esophagectomy is a valuable compo

130 The extent of lymphadenectomy during esophagectomy remains controversi

131 , indicating a therapeutic value of extended lymphadenectomy during esophagectomy.

132 Lymphadenectomy during oesophageal cancer surgery is a s

133 he data provide support in favor of extended lymphadenectomy during potentially curative gastrectomy

134 important prognostic and therapeutic role of lymphadenectomy during radical cystectomy has become app

135 The prognostic role of the extent of lymphadenectomy during surgery for esophageal cancer is

136 This study indicated that the extent of lymphadenectomy during surgery for esophageal cancer mig

137 The prognostic role of lymphadenectomy during surgery for oesophageal cancer is

138 between 1965 and 2009 that compared extended lymphadenectomy (EL) with standard rectal resection.

139 , WLE plus SLND (SLND), or WLE plus elective lymphadenectomy (ELND) for primary melanoma.

140 with breast cancer were staged with sentinel lymphadenectomy followed by completion level I and II ax

141 Of 2,602 patients who underwent complete lymphadenectomy for AJCC stage III melanoma with regiona

142 who undergo radical hysterectomy and pelvic lymphadenectomy for carcinoma of the cervix.

143 n endoscopic mucosectomy or gastrectomy with lymphadenectomy for early gastric cancer depends especia

144 s) represents a quality assurance measure in lymphadenectomy for many solid tumors, the minimum numbe

145 who underwent lymphatic mapping and sentinel lymphadenectomy for melanoma and were followed up for at

146 g times has guided the extent of surgery and lymphadenectomy for MTC.

147 ion and sentinel-node biopsy, with immediate lymphadenectomy for nodal metastases detected on biopsy

148 ent between subjects randomized to SLNB with lymphadenectomy for nodal metastasis on biopsy and subje

149 go wide excision and nodal observation, with lymphadenectomy for nodal relapse (observation group), o

150 and subjects randomized to observation with lymphadenectomy for nodal relapse.

151 high-risk patients, enabling restriction of lymphadenectomy for patients with a low risk of aggressi

152 erapy after radical cystectomy and bilateral lymphadenectomy for patients with muscle-invasive urothe

153 ers, whereas minimally invasive ilioinguinal lymphadenectomy for penile cancer remains exploratory at

154 dical records on 2526 patients who underwent lymphadenectomy for regional LN metastasis associated wi

155 Patients had undergone lymphadenectomy for regional LN metastasis.

156 erienced hands, laparoscopic retroperitoneal lymphadenectomy for renal cell cancer is safe and allows

157 treated by radical cystectomy and bilateral lymphadenectomy for urothelial-cell carcinoma of the bla

158 A minimal lymphadenectomy (groups 1, 2, and 3) was projected to le

159 therapy but the effectiveness and extent of lymphadenectomy has been challenged, and its acceptance

160 As a pelvic lymphadenectomy has complications that generally increas

161 me the predominant approach, use of extended lymphadenectomy has increased with lymph node yield near

162 with elevated markers before retroperitoneal lymphadenectomy have a high rate of relapse and should b

163 invasive disease, nodal status and extent of lymphadenectomy have been shown to correlate with surviv

164 sion and sentinel-node biopsy with immediate lymphadenectomy if nodal micrometastases were detected o

165 ive observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred, or to wide ex

166 intraoperative lymphatic mapping followed by lymphadenectomy if the sentinel node is positive.

167 urthermore, previous studies have shown that lymphadenectomy impairs acquisition of adaptive immune r

168 erapy after radical prostatectomy and pelvic lymphadenectomy improves survival and reduces the risk o

169 uggested that the performance of an extended lymphadenectomy in association with a pancreaticoduodena

170 uggested that the performance of an extended lymphadenectomy in association with a pancreaticoduodena

171 Minimally invasive lymphadenectomy in bladder cancer does not yet approach

172 compared with the gold standard of complete lymphadenectomy in detecting metastatic disease for endo

173 traoperative pathological analyses mean that lymphadenectomy in low-risk patients might still have me

174 he possible therapeutic benefit of selective lymphadenectomy in management of patients with apparent

175 consideration when monitoring the quality of lymphadenectomy in melanoma and can represent entry crit

176 y and the need for extended pelvic and iliac lymphadenectomy in order to optimize an integrated treat

177 sthoracic esophagectomy with en bloc 2-field lymphadenectomy in patients post neoadjuvant chemotherap

178 ew minimally invasive procedure for inguinal lymphadenectomy in patients with penis cancer.

179 dectomy and to consider reoperative cervical lymphadenectomy in patients with persistently elevated c

180 se the current literature on the benefits of lymphadenectomy in patients with renal cell carcinoma.

181 The independent role of the extent of lymphadenectomy in relation to all-cause and disease-spe

182 sion with a 2-cm margin and undergo elective lymphadenectomy in selected circumstances.

183 a reasonable alternative to inguinal femoral lymphadenectomy in selected women with squamous cell car

184 The extent of lymphadenectomy in surgical procedures should respect th

185 f patients undergoing unnecessary, extensive lymphadenectomy in the absence of disease.

186 definition of limited versus extended pelvic lymphadenectomy in the literature is variable, and the i

187 assess the value of extended lateral pelvic lymphadenectomy in the operative management of rectal ca

188 ial cancer metastases and can safely replace lymphadenectomy in the staging of endometrial cancer.

189 The role of esophagectomy with radical lymphadenectomy in the treatment of esophageal cancer is

190 Standardization of pelvic lymphadenectomy in the urologic community is strongly ne

191 nts of lymph node dissection (D1, D2, and D3 lymphadenectomy) in patients affected with operable gast

192 In most cases, the mediastinal lymphadenectomy included the low para-esophageal nodes (

193 rian or endometrial cancer), after a staging lymphadenectomy including resection of SNs related to th

194 reated with surgery, which should include D2 lymphadenectomy (including lymph node stations in the pe

195 e patients than lesser anatomic templates of lymphadenectomy, including some patients with common ili

196 Sentinel lymphadenectomy is a highly accurate technique for ident

197 Furthermore lymphadenectomy is associated with an increase in both s

198 node metastases (LNM) through PET/CT before lymphadenectomy is crucial for successful therapy.

199 Lymphadenectomy is effective for nodal metastasis from M

200 Adequate lymphadenectomy is essential to ensure correct stage all

201 urothelial cancers remain muddled as routine lymphadenectomy is not performed and both open and lapar

202 Concomitant regional lymphadenectomy is of prognostic value, however it is no

203 Lymphadenectomy is performed to assess patient prognosis

204 25 years, it is no longer clear that pelvic lymphadenectomy is pertinent for most men diagnosed toda

205 Selective lymphadenectomy is widely accepted in the management of

206 ral studies have found that a more extensive lymphadenectomy leads to better disease-specific surviva

207 ntraoperative lymphatic mapping and sentinel lymphadenectomy (LM/SL) for identification of occult lym

208 Lymphatic mapping and sentinel lymphadenectomy (LM/SL) have been applied to virtually a

209 Lymphatic mapping and sentinel lymphadenectomy (LM/SL) is standard to stage regional no

210 ntraoperative lymphatic mapping and sentinel lymphadenectomy (LM/SL), the SN is the only tumor-involv

211 ent predictor of margin status or suboptimal lymphadenectomy (<12 lymph nodes harvested).

212 Lymphadenectomy may have beneficial effects on PFS in op

213 is is used to determine the need for further lymphadenectomy, more sensitive intraoperative methods w

214 Furthermore, the extent of lymphadenectomy must be correlated with node location, w

215 mice underwent lymphadenectomy (n = 5), sham lymphadenectomy (n = 5), or no intervention (n = 5), fol

216 study lymphatic flow, C57BL/6 mice underwent lymphadenectomy (n = 5), sham lymphadenectomy (n = 5), o

217 to assess effects of the extent of selective lymphadenectomy on outcomes in women with apparent stage

218 the potentially positive effect of extended lymphadenectomy on survival have been performed in patie

219 stic benefits by extending the boundaries of lymphadenectomy or by increasing the number of nodes exc

220 g preoperative data, and patients in whom no lymphadenectomy or reconstruction was performed were exc

221 tality, independent of the categorization of lymphadenectomy or stratification for T category, calend

222 Following standard lymphadenectomy, patients were treated with DNP vaccine

223 ocedure including hysterectomy and selective lymphadenectomy (pelvic or pelvic + aortic).

224 e, number of removed LNs, and subregions for lymphadenectomy per patient did not differ significantly

225 Compartment-oriented lymphadenectomy performed early in the course of MTC is

226 sisted radical cystectomy (RARC) with pelvic lymphadenectomy (PLND) and urinary diversion for the tre

227 Radical cystectomy and pelvic lymphadenectomy (PLND) remains the standard treatment fo

228 ere subjected to two surgical protocols: (1) lymphadenectomy plus irradiation; and (2) sham surgery a

229 Staging lymphadenectomy poses risks, such as leg lymphedema or l

230 aparoscopic radical cystectomy with extended lymphadenectomy provides short-term functional and oncol

231 ery performed, overall blood loss, extent of lymphadenectomy, rate of resections with negative margin

232 terine carcinoma, the benefits of a complete lymphadenectomy remain controversial.

233 Lymphadenectomy remains the best method to stage prostat

234 Radical cystectomy with thorough pelvic lymphadenectomy remains the gold standard for management

235 e needed to properly establish the extent of lymphadenectomy required to obtain such benefits.

236 Debate continues regarding the extent of lymphadenectomy required when carrying out an esophagect

237 bilateral salpingo-oophorectomy, and pelvic lymphadenectomy revealed International Federation of Gyn

238 rveillance, chemotherapy, or retroperitoneal lymphadenectomy (RPLND) with similar survival outcomes.

239 enerally increase with extent of dissection, lymphadenectomy should be limited to patients at an incr

240 metastases at the time of operation, central lymphadenectomy should be performed.

241 is pertinent, it is unclear how extensive a lymphadenectomy should be performed.

242 Lymphadenectomy should be strongly considered for ICC, b

243 Therefore, an extended lymphadenectomy should be the standard of care after nCR

244 ection of axillary metastases using sentinel lymphadenectomy (SLND) and immunohistochemistry.

245 illary lymphadenectomy (ALND) after sentinel lymphadenectomy (SLND) has confirmed that tumor-negative

246 European investigators suggest that sentinel lymphadenectomy (SLND), a mainstay of melanoma diagnosis

247 -3 N1-3 M0) radical prostatectomy and pelvic lymphadenectomy specimens.

248 ith stratification for participating centre, lymphadenectomy, stage of cancer, and histological type.

249 ith stratification for participating centre, lymphadenectomy, stage, and histological type.

250 tes and a key summary on the developments in lymphadenectomy templates in kidney, prostate and bladde

251 s higher among those who underwent immediate lymphadenectomy than among those in whom lymphadenectomy

252 We sought to determine the extent of lymphadenectomy that optimizes staging and survival in p

253 Clinical Application: Compared with D1 lymphadenectomy (the most conservative type of lymph nod

254 hether all low-risk patients need a complete lymphadenectomy, the limitations of preoperative and int

255 of a distal gastrectomy and retroperitoneal lymphadenectomy to a pylorus-preserving pancreaticoduode

256 tal gastrectomy and extended retroperitoneal lymphadenectomy to a standard pancreaticoduodenectomy) c

257 The optimal extent of lymphadenectomy to enhance both staging and survival fol

258 metastases suggesting that a more systematic lymphadenectomy to extirpate occult disease may be indic

259 What constitutes optimum lymphadenectomy to maximize survival is controversial be

260 domly assigned after radical nephrectomy and lymphadenectomy to observation or to interferon alfa-NL

261 egan the international Multicenter Selective Lymphadenectomy Trial (MSLT) 5 years ago to evaluate the

262 egan the international Multicenter Selective Lymphadenectomy Trial (MSLT-I) to compare 2 treatment ap

263 nterim analysis of the Multicenter Selective Lymphadenectomy Trial 1 (MSLT-1).

264 SLNB in melanoma, the Multicenter Selective Lymphadenectomy Trial I was performed.

265 subject of the ongoing Multicenter Selective Lymphadenectomy Trial II.

266 The phase III Multicenter Selective Lymphadenectomy Trial will definitively settle the issue

267 ng phase of the second Multicenter Selective Lymphadenectomy Trial.

268 r undergoing radical hysterectomy and pelvic lymphadenectomy using preoperative and intraoperative ly

269 ected prognosis of carrying out less radical lymphadenectomies was calculated according to 3 groups:

270 0 cancers and 1 to 6 nodes positive, optimum lymphadenectomy was 10 for pT1, 15 for pT2, and 29 to 50

271 ymphadenectomy was defined for pTis; optimum lymphadenectomy was 10 to 12 nodes for pT1, 15 to 22 for

272 after orchiectomy and before retroperitoneal lymphadenectomy was a significant independent predictor

273 Greater extent of lymphadenectomy was associated with increased survival f

274 vant ypTNM cancer categories, some degree of lymphadenectomy was associated with longer lifetime, but

275 A threshold for an adequate lymphadenectomy was defined as retrieval of 12 nodes.

276 In pN0M0 cancers, no optimum lymphadenectomy was defined for pTis; optimum lymphadene

277 ate lymphadenectomy than among those in whom lymphadenectomy was delayed (72.3+/-4.6% vs. 52.4+/-5.9%

278 omy was done in 340 patients and para-aortic lymphadenectomy was done in 196 (58%) of these patients.

279 inel-lymph-node mapping with complete pelvic lymphadenectomy was done in 340 patients and para-aortic

280 agectomy with two-field (abdomen and thorax) lymphadenectomy was done within 4-6 weeks of completion

281 One patient who did not undergo lymphadenectomy was excluded from the pathology data ana

282 Performance of aortic selective lymphadenectomy was not associated with survival.

283 The extent of lymphadenectomy was not statistically significantly asso

284 When paratracheal lymphadenectomy was performed during an Ivor Lewis or a

285 rwent sentinel lymph node biopsy; completion lymphadenectomy was performed for patients with sentinel

286 Between 1991 and 1997, axillary lymphadenectomy was performed in 157 women with a tumor-

287 Lymphadenectomy was performed in 248 patients (55%); 74

288 Extended (D2) lymphadenectomy was performed in 75% of cases.

289 D2 or D2+ lymphadenectomy was performed in almost 80% of operation

290 Adequate lymphadenectomy was significantly more likely in patient

291 e capable of metastasizing and therefore, if lymphadenectomy was still adequate.

292 ised controlled trial, D1 resection (level 1 lymphadenectomy) was compared with D2 resection (levels

293 (PSMA) HBED-CC PET/CT or PET/MR and salvage lymphadenectomy were retrospectively included.

294 ology, the efficacy, safety, and adequacy of lymphadenectomy were reviewed for studies about prostate

295 IIIB) who were melanoma-free after standard lymphadenectomy were treated with multiple intradermal i

296 Our data thus show a prognostic relevance of lymphadenectomy which should therefore be retained until

297 This study suggests that extended lymphadenectomy with dissection of the nerve plexus does

298 ntinel-lymph-node mapping followed by pelvic lymphadenectomy with or without para-aortic lymphadenect

299 e cancer as well as bladder cancer, extended lymphadenectomy with resection of external and internal

300 sease after radical cystectomy and bilateral lymphadenectomy, with no evidence of any microscopic res

301 dical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transition